A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19

Antimicrobial Agents and Chemotherapy

Volumn 64, Issue 9, 2020, Pages

  Davoudi Monfared, Effat ^a   Rahmani, Hamid ^a   Khalili, Hossein ^a   Hajiabdolbaghi, Mahboubeh ^a   Salehi, Mohamadreza ^a   Abbasian, Ladan ^a   Kazemzadeh, Hossein ^b   Yekaninejad, Mir Saeed ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clinical response; COVID 19; Interferon; Mortality

Indexed keywords

ANTIBIOTIC AGENT; ASCORBIC ACID; ATAZANAVIR PLUS RITONAVIR; AZITHROMYCIN; BETA1A INTERFERON; DEXAMETHASONE; HERBACEOUS AGENT; HYDROCORTISONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LOPINAVIR PLUS RITONAVIR; METHYLPREDNISOLONE; NITROGEN; UREA; ANTIVIRUS AGENT; ATAZANAVIR; LOPINAVIR; LOPINAVIR-RITONAVIR DRUG COMBINATION; RITONAVIR;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANOREXIA; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; APACHE; ARTICLE; BREATHING RATE; CARDIOVASCULAR DISEASE; CHILL; CLINICAL ARTICLE; COMBINATION DRUG THERAPY; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; CORTICOSTEROID THERAPY; COUGHING; DEEP VEIN THROMBOSIS; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPNEA; FEMALE; FEVER; HEADACHE; HERBAL MEDICINE; HONEY; HOSPITAL ADMISSION; HOSPITAL INFECTION; HOSPITAL MORTALITY; HOSPITALIZATION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOTHYROIDISM; INJECTION SITE REACTION; INTENSIVE CARE UNIT; LENGTH OF STAY; LIVER FAILURE; MACULOPAPULAR RASH; MALAISE; MALE; MALIGNANT NEOPLASM; MYALGIA; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SEPTIC SHOCK; STRESS ULCER; SUBCUTANEOUS IMMUNOTHERAPY; THORAX PAIN; THROMBOSIS PREVENTION; THYME; TREATMENT RESPONSE TIME; UREA NITROGEN BLOOD LEVEL; BETACORONAVIRUS; COMORBIDITY; CORONAVIRUS INFECTION; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; IMMUNOLOGY; MIDDLE AGED; MORTALITY; NEOPLASM; PANDEMIC; PATHOGENICITY; PATIENT SAFETY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIROLOGY; VIRUS PNEUMONIA;

ADULT; AGED; ANTIVIRAL AGENTS; ATAZANAVIR SULFATE; BETACORONAVIRUS; CARDIOVASCULAR DISEASES; COMORBIDITY; CORONAVIRUS INFECTIONS; DIABETES MELLITUS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; INTENSIVE CARE UNITS; INTERFERON BETA-1A; LENGTH OF STAY; LOPINAVIR; MALE; MIDDLE AGED; NEOPLASMS; PANDEMICS; PATIENT SAFETY; PNEUMONIA, VIRAL; RITONAVIR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85089787512     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01061-20     Document Type: Article

References (51)

1. Wang C, Horby PW, Hayden FG, Gao GF. 2020. A novel coronavirus outbreak of global health concern. Lancet 395:470 – 473. https://doi.org/10.1016/S0140-6736(20)30185-9.
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395: 1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3.
3. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. 2020. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 180: e200994. https://doi.org/10.1001/jamainternmed.2020.0994.
4. World Health Organization. 2020. WHO coronavirus disease (COVID-19) dashboard. World Health Organization, Geneva, Switzerland. https://covid19.who.int/?gclid=Cj0KCQjwl4v4BRDaARIsAFjATPmRcsB7VPlJAx JMhXU5bnYKH2jMgjcLtozUR_fRAeH7rKbf_PV7IbIaAuU6EALw_ wcB. Accessed 6 July 2020.
5. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. 2020. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382:1787–1799. https://doi.org/10.1056/NEJMoa2001282.
6. Gao J, Tian Z, Yang X. 2020. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14:72–73. https://doi.org/10.5582/bst.2020.01047.
7. Meyerowitz E1, Vannier AGL, Friesen MGN, Schoenfeld S, Gelfand JA, Callahan MV, Kim AY, Reeves PM, Poznansky MC. 2020. Rethinking the role of hydroxychloroquine in the treatment of COVID-19. FASEB J 34:6027–6037. https://doi.org/10.1096/fj.202000919.
8. Cunningham AC, Goh HP, Koh D. 2020. Treatment of COVID-19: old tricks for new challenges. Crit Care 24:91. https://doi.org/10.1186/s13054-020-2818-6.
9. Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, Clementi M, Dianzani F, Antonelli G. 2004. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther 9:1003–1011.
10. Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, Li PT, Dai J, Mok FK, Chen H, Hayden FG, Yuen KY. 2013. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 67: 606–616. https://doi.org/10.1016/j.jinf.2013.09.029.
11. Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, Olinger GG, Frieman MB, Holbrook MR, Jahrling PB, Hensley L. 2014. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 95:571–577. https://doi.org/10.1099/vir.0.061911-0.
12. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE, Bauer L, Sellers S, Porter D, Feng JY, Cihlar T, Jordan R, Denison MR, Baric RS. 2020. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 11:222. https://doi.org/10.1038/s41467-019-13940-6.
13. Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, Kojan S, Al Jeraisy M, Deeb AM, Assiri AM, Al-Hameed F, AlSaedi A, Mandourah Y, Almekhlafi GA, Sherbeeni NM, Elzein FE, Memon J, Taha Y, Almotairi A, Maghrabi KA, Qushmaq I, Al Bshabshe A, Kharaba A, Shalhoub S, Jose J, Fowler RA, Hayden FG, Hussein MA, the MIRACLE trial group. 2018. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 19:81. https://doi.org/10.1186/s13063-017-2427-0.
14. Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. 2020. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res 178:104791. https://doi.org/10.1016/j.antiviral.2020.104791.
15. Bellingan G, Maksimow M, Howell DC, Stotz M, Beale R, Beatty M, Walsh T, Binning A, Davidson A, Kuper M, Shah S, Cooper J, Waris M, Yegutkin GG, Jalkanen J, Salmi M, Piippo I, Jalkanen M, Montgomery H, Jalkanen S. 2014. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir Med 2:98–107. https://doi.org/10.1016/S2213-2600(13)70259-5.
16. Ranieri VM, Pettilä V, Karvonen MK, Jalkanen J, Nightingale P, Brealey D, Mancebo J, Ferrer R, Mercat A, Patroniti N, Quintel M, Vincent JL, Okkonen M, Meziani F, Bellani G, MacCallum N, Creteur J, Kluge S, Artigas-Raventos A, Maksimow M, Piippo I, Elima K, Jalkanen S, Jalkanen M, Bellingan G, INTEREST Study Group. 2020. Effect of intravenous interferon β-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: a randomized clinical trial. JAMA 323:725. https://doi.org/10.1001/jama.2019.22525.
17. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. 2020. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 92:814–818. https://doi.org/10.1002/jmv.25801.
18. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X, Zhang S. 2020. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol 214:108393. https://doi.org/10.1016/j.clim.2020.108393.
19. Zhang S, Li L, Shen A, Chen Y, Qi Z. 2020. Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Clin Drug Investig 40: 511–518. https://doi.org/10.1007/s40261-020-00917-3.
20. Roback JD, Guarner J. 2020. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA 323:1561. https://doi.org/10.1001/jama.2020.4940.
21. Cinat J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. 2003. Treatment of SARS with human interferons. Lancet 362:293–294. https://doi.org/10.1016/S0140-6736(03)13973-6.
22. Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, Jose J, Alraddadi B, Almotairi A, Al Khatib K, Abdulmomen A, Qushmaq I, Sindi AA, Mady A, Solaiman O, Al-Raddadi R, Maghrabi K, Ragab A, Al Mekhlafi GA, Balkhy HH, Al Harthy A, Kharaba A, Gramish JA, Al-Aithan AM, Al-Dawood A, Merson L, Hayden F, Fowler R. 2020. Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study. Clin Infect Dis 70: 1837–1844. https://doi.org/10.1093/cid/ciz544.
23. Hung IF, Lung KC, Tso EY, Liu R, Chung TWH, Chu MY, Ng YY, Lo J, Chan J, Tam AR, Shum HP, Chan V, Wu AKL, Sin KM, Leung WS, Law WL, Lung DC, Sin S, Yeung P, Yip CCY, Zhang RR, Fung AYF, Yan EYW, Leung KH, Ip JD, Chu AWH, Chan WM, Ng ACK, Lee R, Fung K, Yeung A, Wu TC, Chan JWM, Yan WW, Chan WM, Chan JFW, Lie AKW, Tsang OTY, Cheng VCC, Que TL, Lau CS, Chan KH, To KKW, Yuen KY. 2020. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395:1695–1704. https://doi.org/10.1016/S0140-6736(20)31042-4.
24. Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, Wang ZH, Tebbutt SJ, Kollmann TR, Fish EN. 2020. Interferon-α2b treatment for COVID-19. Front Immunol 11:1061. https://doi.org/10.3389/fimmu.2020.01061.
25. Su S, Jiang S. 2020. A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2. Signal Transduct Target Ther 5:71. https://doi.org/10.1038/s41392-020-0185-z.
26. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR. 2020. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181:1036–1045. https://doi.org/10.1016/j.cell.2020.04.026.
27. Kopecky-Bromberg SA, Martínez-Sobrido L, Frieman M, Baric RA, Palese P. 2007. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol 81:548–557. https://doi.org/10.1128/JVI.01782-06.
28. Frieman M, Yount B, Heise M, Kopecky-Bromberg SA, Palese P, Baric RS. 2007. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol 81:9812–9824. https://doi.org/10.1128/JVI.01012-07.
29. Lokugamage KG, Schindewolf C, Menacher VD. 2020. SARS-CoV-2 sensitive to type I interferon pretreatment. BioRxiv https://doi.org/10.1101/2020.03.07.982264.
30. Flammer JR, Dobrovolna J, Kennedy MA, Chinenov Y, Glass CK, Ivashkiv LB, Rogatsky I. 2010. The type I interferon signaling pathway is a target for glucocorticoid inhibition. Mol Cell Biol 30:4564–4574. https://doi.org/10.1128/MCB.00146-10.
31. Chen X, Zheng F, Qing Y, Ding S, Yang D, Lei C, Yin Z, Zhou X, Jiang D, Zuo Q, He J, Lv J, Chen P, Chen Y, Peng H, Li H, Xie Y, Liu J, Zhou Z, Luo H. 2020. Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a double-center observational study. medRxiv https://doi.org/10.1101/2020.03.03.20030353.
32. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. 2020. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicenter trial. Lancet 395:1569–1578. https://doi.org/10.1016/S0140-6736(20)31022-9.
33. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shan Y. 2020. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 8:475–481. https://doi.org/10.1016/S2213-2600(20)30079-5.
34. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. 2020. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv https://doi.org/10.1101/2020.01.26.919985.
35. Cai H. 2020. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med 8:e20. https://doi.org/10.1016/S2213-2600 (20)30117-X.
36. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, de Castilla DL, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, ACTT-1 Study Group Members. 22 May 2020. Remdesivir for the treatment of Covid-19 —preliminary report. N Engl J Med. https://doi.org/10.1056/NEJMoa2007764.
37. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG, Chen YS, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wei X, Gaggar A, Brainard DM, Towner WJ, Muñoz J, Mullane KM, Marty FM, Tashima KT, Diaz G, Subramanian A, GS-US-540–5773 Investigators. 16 May 2020. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med https://doi.org/10.1056/NEJMoa2015301.
38. Weiss P, Murdoch DR. 2020. Clinical course and mortality risk of severe COVID-19. Lancet 395:1014–1015. https://doi.org/10.1016/S0140-6736 (20)30633-4.
39. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M. 2020. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 323:1612–1614. https://doi.org/10.1001/jama.2020.4326.
40. Cao W, Li T. 2020. COVID-19: towards understanding of pathogenesis. Cell Res 30:367–369. https://doi.org/10.1038/s41422-020-0327-4.
41. Channappanavar R, Fehr AR, Zheng J, Wohlford-Lenane C, Abrahante JE, Mack M, Sompallae R, McCray PB, Meyerholz DK, Perlman S. 2019. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Investig 129:3625–3639. https://doi.org/10.1172/JCI126363.
42. Hu X, Miller L, Richman S, Hitchman S, Glick G, Liu S, Zhu Y, Crossman M, Nestorov I, Gronke RS, Baker DP, Rogge M, Subramanyam M, Davar G. 2012. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol 52:798–808. https://doi.org/10.1177/0091270011407068.
43. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, Jiang B. 2020. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet 395:e52. https://doi.org/10.1016/S0140-6736(20)30558-4.
44. National Institute of Diabetes and Digestive and Kidney Diseases. 2017. LiverTox: clinical and research information on drug-induced liver injury. Atanazir. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. https://www.ncbi.nlm.nih.gov/books/NBK547918/.
45. Wu Z, McGoogan JM. 2020. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323:1239. https://doi.org/10.1001/jama .2020.2648.
46. Khwaja A. 2012. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120:c179–c184. https://doi.org/10.1159/000339789.
47. Peterson RL, Vock DM, Powers JH, Emery S, Cruz EF, Hunsberger S, Jain MK, Pett S, Neaton JD, INSIGHT FLU-IVIG Study Group. 2017. Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization. Clin Trials 14:264–276. https://doi.org/10.1177/1740774517697919.
48. Lescot T, Karvellas C, Beaussier M, Magder S. 2012. Acquired liver injury in the intensive care unit. Anesthesiology 117:898–904. https://doi.org/10.1097/ALN.0b013e318266c6df.
49. Singh A, Jialal I. 2020. Unconjugated hyperbilirubinemia. In StatPearls. StatPearls Publishing, Treasure Island, FL.
50. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. 2017. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock. Intensive Care Med 43:304–377. https://doi.org/10.1007/s00134-017-4683-6.
51. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. 1981. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245. https://doi.org/10.1038/clpt.1981.154.